Abstract:Drug-induced blockade of the human ether-à-go-go-related gene (hERG) channel is today considered the main cause of cardiotoxicity in postmarketing surveillance. Hence, several ligand-based approaches were developed in the last years and are currently employed in the early stages of a drug discovery process for in silico cardiac safety assessment of drug candidates. Herein, we present the first structure-based classifiers able to discern hERG binders from nonbinders. LASSO regularized support vector machines were applied to integrate docking scores and protein–ligand interaction fingerprints. A total of 396 models were trained and validated based on: (i) high-quality experimental bioactivity information returned by 8337 curated compounds extracted from ChEMBL (version 25) and (ii) structural predictor data. Molecular docking simulations were performed using GLIDE and GOLD software programs and four different hERG structural models, namely, the recently published structures obtained by cryoelectron microscopy (PDB codes: 5VA1 and 7CN1) and two published homology models selected for comparison. Interestingly, some classifiers return performances comparable to ligand-based models in terms of area under the ROC curve (AUCMAX = 0.86 ± 0.01) and negative predictive values (NPVMAX = 0.81 ± 0.01), thus putting forward the herein proposed computational workflow as a valuable tool for predicting hERG-related cardiotoxicity without the limitations of ligand-based models, typically affected by low interpretability and a limited applicability domain. From a methodological point of view, our study represents the first example of a successful integration of docking scores and protein–ligand interaction fingerprints (IFs) through a support vector machine (SVM) LASSO regularized strategy. Finally, the study highlights the importance of using hERG structural models accounting for ligand-induced fit effects and allowed us to select the best-performing protein conformation (made available in the Supporting Information, SI) to be employed for a reliable structure-based prediction of hERG-related cardiotoxicity.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jcim.1c00744.Top views of the BS of all of the employed protein models and the number of active and inactive compounds as a consequence of the selected activity and inactivity thresholds (Figures S1 and S2 and Tables S1) (PDF)Kolmogorov–Smirnov test p-values summarizing the difference in docking score distributions between hERG binders and nonbinders, the SE and SP of all of the developed models, the BS volumes (Å3) of all of the used hERG models, and the interactions responsible for a lower IC50 based on the KS test performed on the IFs returned by all of the considered protein models (Tables S2–S6) (PDF)List of the compounds belonging to the hERG-DB, including SMILES strings and corresponding IC50 values (XLSX)Results of the performed docking simulations including docking scores and molecular interaction fingerprints (ZIP)Results of the performed docking simulations including molecular interaction fingerprints (ZIP)5VA1-IFD-1, 5VA1-IFD-2, 5VA1-IFD-3, 5VA1-IFD-4, and 5VA1-IFD-5 conformations as. pdb files (ZIP)This article has not yet been cited by other publications.

Logic-based machine learning predicts how escitalopram attenuates cardiomyocyte hypertrophy

Virtual drug screen reveals context-dependent inhibition of cardiomyocyte hypertrophy

Machine Learning‐Based Prediction of Escitalopram and Sertraline Side Effects with Pharmacokinetic Data in Children and Adolescents

Endothelial Klf2-Foxp1-TGF signal mediates the inhibitory effects of simvastatin on maladaptive cardiac remodeling

Enhanced drug classification using machine learning with multiplexed cardiac contractility assays

Effect of escitalopram on Aβ levels and plaque load in an Alzheimer mouse model

Computational Modeling on Drugs Effects for Left Ventricle in Cardiomyopathy Disease

Machine learning-based prediction model for the efficacy and safety of statins

Pro-arrhythmic effect of escitalopram and citalopram at serum concentrations commonly observed in older patients - a study based on a cohort of 19,742 patients

Predicting escitalopram treatment response from pre-treatment and early response resting state fMRI in a multi-site sample: A CAN-BIND-1 report

Abstract 9682: The Cardiac Protective Effects of Novel Synthetic Pan-Estrogen Related Receptor Agonists Slu-pp-332 and Slu-pp-915

Artificial intelligence-enhanced risk stratification of cancer therapeutics-related cardiac dysfunction using electrocardiographic images

Structure-Based Prediction of hERG-Related Cardiotoxicity: A Benchmark Study

Predicting Escitalopram Monotherapy Response in Depression: the Role of Anterior Cingulate Cortex

Predicting the efficacy of escitalopram in the treatment of depression through urinary proteome

Optical microscopy imaging for the diagnosis of the pharmacological reaction of mouse embryonic stem cell-derived cardiomyocytes (mESC-CMs)

MEDICASCY: A Machine Learning Approach for Predicting Small Molecule Drug Side Effects, Indications, Efficacy and Mode of Action.

CardioGenAI: A Machine Learning-Based Framework for Re-Engineering Drugs for Reduced hERG Liability

Inhibiting glycosphingolipids alleviates cardiac hypertrophy by reducing reactive oxygen species and restoring autophagic homeostasis

Large-scale in Silico Identification of Drugs Exerting Sex-Specific Effects in the Heart